R
An experimental drug, daraxonrasib, developed by Revolution Medicines, has shown promise in nearly doubling survival time for patients with advanced pancreatic cancer during clinical trials, despite a high rate of mostly manageable side effects, according to a recently reported study. #PancreaticCancer #ClinicalTrials #CancerResearch #US #IN
www.reuters.com
Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects
May 6 (Reuters) - An experimental drug from Revolution Medicines (RVMD. O), opens new tab that nearly doubled survival time for patients with advanced pancreas cancer in clinical trials comes with a high rate of mostly low-grade side effects, researchers reported on Wednesday.